LIGAND PHARMS BETA CVR (LGNZZ) Debt by Year
LIGAND PHARMS BETA CVR held $174.9M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters LIGAND PHARMS BETA CVR has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
LGNZZ Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | $0-100.0% | $320.7M-27.5% | $442.3M-30.8% | $639.0M+4.8% | $609.9Mn/m | $0 | N/A | $0-100.0% | $195.9M | N/A | $27.5M | N/A |
| Cash & Equivalents | $174.9M+141.9% | $72.3M+215.0% | $23.0M-49.0% | $45.0M+130.5% | $19.5M-59.0% | $47.6M-33.4% | $71.5M-38.9% | $117.2M+468.2% | $20.6M+10.0% | $18.8M-80.8% | $97.4M-39.2% | $160.2M+1276.4% | $11.6M-6.0% | $12.4M+75.8% | $7.0M |
LGNZZ Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $679.9M | $1.1B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $56.0M-59.9% | $1.0B+1387.7% | $115.1M+139.8% | $174.9M+141.9% | $139.4M+119.1% | $67.7M+273.1% | $48.0M-4.2% | $72.3M+215.0% | $63.6M+230.1% | $18.1M-36.2% | $50.1M-43.5% | $23.0M-49.0% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More LIGAND PHARMS BETA CVR financials
Frequently Asked Questions
What was LIGAND PHARMS BETA CVR's long-term debt in fiscal year 2025?
LIGAND PHARMS BETA CVR held $174.9M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period.
What was LIGAND PHARMS BETA CVR's long-term debt in the most recent quarter?
LIGAND PHARMS BETA CVR (LGNZZ) reported $679.9M in long-term debt in Q3 2026.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what LIGAND PHARMS BETA CVR (LGNZZ) reported on that line in every period on record.